Tag:
Susan Desmond-Hellmann
Latest Headlines
Latest Headlines
Sanofi adds diabetes to collaborative effort at UCSF
Sanofi ( $SNY ) is broadening its research ties with the University of California in San Francisco, which has been steadily growing its collaborative work with the biopharma industry under Chancellor
UCSF's Desmond-Hellmann envisions a biotech empire on the Bay
Susan Desmond-Hellmann is pushing to make the University of California, San Francisco an international powerhouse in the world of drug discovery. Profiled in an in-depth article in The New York
Genentech and UCSF to join forces on drug development
In the most recent example of the growing relationship between drug developers and academic research teams, Genentech has inked a partnership deal with investigators at UC San Francisco to develop
Genentech exec to top up UCSF
Genentech's loss apparently will be UCSF's gain. Dr. Susan Desmond-Hellmann ( photo ), the company's ex-president of product development, appears to be headed for the chancellorship at University of
Desmond-Hellmann to become chancellor at UCSF
Soon after Roche completed its takeover of Genentech, it was apparent that Susan Desmond-Hellmann ( photo ) would be stepping aside from her starring role as head of product development. It turns out
Genentech execs hit the door as Roche takes over
The game of musical chairs at the newly-acquired Genentech has begun. And it's starting at the top. Genentech CEO Arthur Levinson ( photo ) has been handed the role of chairman of a new board of
Genentech's newly-rich scientists could pose a challenge
Roche has several big challenges waiting for it at Genentech. One example: Its $47 billion takeover of the biotech giant will make many of the California biotech's scientists rich. Very, very rich.
Development chief outlines strategy at Genentech
Genentech's Susan Desmond-Hellmann, president of product development, outlined the biotech giant's development strategy to a group at the Goldman Sachs healthcare conference. In addition to testing
